SOPHiA GENETICS SA SOPH
EDP Services · IPO 2021 · data as of November 13, 2026
SOPHiA GENETICS SA (SOPH) is a technology company listed in the US with a market value of about $699M. In the twelve months to September 30, 2026 it had revenue of $91M and net income of -$81M, a net margin of -89.2%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 22% a year, a 5-year average ROIC of -42%.
About SOPHiA GENETICS SA
SOPHiA GENETICS SA is listed in the US and classified in edp services, IPO year 2021. Revenue went from $25M in 2019 to $77M in 2025, growth of about 20.4% a year. It was profitable in 0 of the last 7 years in our data.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $91M | $77M | $65M | $62M | $48M | $40M | $28M | $25M |
| Net income | -$81M | -$79M | -$62M | -$79M | -$87M | -$74M | -$39M | -$34M |
| Free cash flow | -$51M | -$36M | -$45M | -$55M | -$74M | -$61M | -$32M | -$33M |
| EPS (diluted) | $-1.09 | $-0.93 | $-0.73 | $-0.93 | $-1.03 | $-0.87 | $-0.46 | $-0.40 |
| Net margin | -89.2% | -102.2% | -95.9% | -126.6% | -183.9% | -182.1% | -138.5% | -133.2% |
| ROIC | — | -59.0% | -47.9% | -39.0% | -43.8% | -20.5% | -34.4% | -98.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $9.75, 19% above the current price; targets range from $7.00 to $14.00; the consensus rating is “Strong buy”; expected EPS is $-0.88 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does SOPHiA GENETICS SA pay a dividend?
Not currently.
Is SOPHiA GENETICS SA a good stock to buy?
We do not give buy or sell advice. SOPHiA GENETICS SA scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.